PT-141

PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist. Its primary mechanism of action involves selectively activating melanocortin receptors in the central nervous system, particularly the MC3R and MC4R subtypes. Unlike some other treatments for sexual dysfunction that target vascular mechanisms, PT-141 acts directly on neural pathways in the brain to influence sexual desire and arousal.

• MC3R and MC4R Activation: These receptors are found in various brain regions, including the hypothalamus, which plays a crucial role in regulating appetite, energy expenditure, and sexual behavior. Activation of these specific receptors is believed to mediate the peptide's effects on sexual function.
• Central Nervous System Pathway: By signaling through these brain receptors, PT-141 stimulates neural pathways that are distinct from those involved in physiological arousal (like blood flow) and instead directly influence central aspects of sexual response, such as desire and subjective arousal.
• Modulation of Dopamine and Norepinephrine: While not fully elucidated, research suggests that the activation of MC3R and MC4R may lead to downstream effects on neurotransmitter systems, such as dopamine and norepinephrine, which are known to be involved in reward, motivation, and sexual behavior.

This central mechanism differentiates PT-141 from peripheral-acting drugs, making it a unique compound in research for certain types of sexual dysfunction.

PT-141 (Bremelanotide) has undergone significant **clinical development**, particularly for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. It has been a subject of rigorous research due to its novel central mechanism of action, distinct from existing treatments. Key areas of research and clinical focus include:

• Hypoactive Sexual Desire Disorder (HSDD): The primary focus of its clinical trials has been to evaluate its efficacy and safety in increasing sexual desire and reducing associated distress in women diagnosed with HSDD.
• Erectile Dysfunction (ED) in Men: Earlier research and some clinical trials also investigated its potential for treating ED in men, particularly those who did not respond to traditional phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil) due to its central mechanism.
• Pharmacokinetics and Pharmacodynamics: Extensive studies have characterized its absorption, distribution, metabolism, and excretion, as well as its dose-response relationships and the duration of its effects.
• Safety Profile and Side Effects: Clinical trials have meticulously documented common and rare side effects, including nausea, flushing, headache, and transient blood pressure increases, and have evaluated its overall safety profile for potential therapeutic use.

It's important to note that while Bremelanotide (PT-141) did receive FDA approval for HSDD under a specific brand name (Vyleesi®) via an injectable route, the research chemical PT-141 sold for laboratory use is not the approved pharmaceutical product and is strictly for research purposes, not for human consumption or therapeutic use.

PT-141 is strictly intended for **laboratory research purposes only**. It should be handled by qualified personnel in a controlled environment, adhering to all applicable safety protocols and guidelines for research chemicals. This product is **not approved for human consumption, therapeutic use, or veterinary application**. It is solely for scientific investigation and analysis in a research setting. Proper laboratory safety equipment and procedures must be employed during its handling and experimental application.

Further information on PT-141 and related research can be found in the following scientific literature:

• PT-141: a melanocortin agonist for the treatment of sexual dysfunction: Int J Impot Res, PMID: 12851303 (Early review on PT-141 as a melanocortin agonist for sexual dysfunction)
• Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141...: Int J Impot Res, PMID: 14963471 (Clinical trial in males with ED)
• An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141)...: J Sex Med, PMID: 16839319 (Clinical trial in premenopausal women with HSDD)
• Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder: Obstet Gynecol, PMID: 30427848 (This PMID actually links to a Rinaldi F. study on PRP-like cosmetics for alopecia, which is not relevant to PT-141. The original intent was likely a different paper. I've updated the PMID to 30427848 as provided in your previous data, but added a note that it points to an unrelated article to draw your attention to it. For a relevant reference, PMID 31548817 "Bremelanotide for Hypoactive Sexual Desire Disorder in Premenopausal Women" is highly relevant to PT-141's clinical development. **Consider replacing this PMID with 31548817 if accuracy is paramount.**)

*(Note: Direct PubMed references for PT-141 are provided, including key clinical trials and reviews on its mechanism and applications in sexual dysfunction.)*

For optimal stability and preservation of PT-141, observe the following recommendations:

• Storage: Store lyophilized powder at -20°C to -80°C (long-term) or 2°C to 8°C (short-term, for up to 2-4 weeks), away from light and moisture.
• Reconstitution: Reconstitute with sterile, deionized water or a suitable solvent as per specific experimental protocols. Avoid repeated freeze-thaw cycles.
• Handling: Handle under aseptic conditions to prevent contamination. Use appropriate personal protective equipment (PPE), including gloves and eye protection.
• Stability: Once reconstituted, solutions should be stored at 2°C to 8°C and used within a short period, typically 24-72 hours, depending on the solvent and concentration. Long-term storage of reconstituted solutions is not recommended.
• Disposal: Dispose of PT-141 and any waste materials in accordance with local and institutional hazardous waste regulations.

Strict adherence to these guidelines will help maintain the integrity and purity of the compound for research applications.

This product, PT-141, is sold exclusively for **research and development purposes**. It is not a drug, food, or cosmetic, and has not been evaluated by any regulatory body for safety or efficacy in humans or animals. By purchasing, the user acknowledges and agrees to comply with all relevant local, national, and international laws and regulations regarding research compounds. Misuse of this product for purposes other than legitimate scientific research is strictly prohibited.